D-0742-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0742-2021 was initiated by Teva Pharmaceuticals USA on Jul 29, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 4, 2024). Affected quantity: 2,199 vials.

Recall details

Product Type
Drugs
Report Date
Aug 25, 2021
Initiation Date
Jul 29, 2021
Termination Date
Jun 4, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,199 vials

Product description

Alprostadil Injection USP, 500 mg/mL, 1 mL single dose, vials, 5 mL single use vial per carton (NDC 0703-1501-02), Rx only, Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, Vial NDC 0703-1501-01

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Product was distributed Nationwide, including Puerto Rico.

Code information

Lot #: 31329295B, exp date. 01/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0742-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0742-2021. Report a data issue: hello@regdatalab.com.